Pipeline Previews

By No Comments
Merck and MK-3475 for Advanced Melanoma Merck has announced that the FDA has accepted for review the Biologics License Application (BLA) for MK-3475, Merck’s investigational anti-PD-1 antibody, for the treatment…
Read More

Biosimilars

By No Comments
Biologic agents are complex protein monoclonal antibodies such as adalimumab and ustekinumab, and genetically engineered recombinant fusion proteins such as etanercept. These agents have added greatly to the therapeutic armamentarium…
Read More